Advanced search
1 file | 501.01 KB Add to list

Protein-protein interactions: network analysis and applications in drug discovery

Jennyfer Bultinck (UGent) , Sam Lievens (UGent) and Jan Tavernier (UGent)
(2012) CURRENT PHARMACEUTICAL DESIGN. 18(30). p.4619-4629
Author
Organization
Abstract
Physical interactions among proteins constitute the backbone of cellular function, making them an attractive source of therapeutic targets. Although the challenges associated with targeting protein-protein interactions (PPIs) -in particular with small molecules are considerable, a growing number of functional PPI modulators is being reported and clinically evaluated. An essential starting point for PPI inhibitor screening or design projects is the generation of a detailed map of the human interactome and the interactions between human and pathogen proteins. Different routes to produce these biological networks are being combined, including literature curation and computational methods. Experimental approaches to map PPIs mainly rely on the yeast two-hybrid (Y2H) technology, which have recently shown to produce reliable protein networks. However, other genetic and biochemical methods will be essential to increase both coverage and resolution of current protein networks in order to increase their utility towards the identification of novel disease-related proteins and PPIs, and their potential use as therapeutic targets.
Keywords
small molecule, drug discovery, oncology, virology, SMALL-MOLECULE INHIBITOR, CHEMICAL CROSS-LINKING, INTERACTION DATABASE, INTERACTION DATASETS, MASS-SPECTROMETRY, SYSTEMS BIOLOGY, DISEASE GENES, THERAPEUTIC SUPPRESSION, HUNTINGTONS-DISEASE, SUBNETWORK MARKERS, interactome, Protein-protein interaction

Downloads

  • Bultinck et al 2012 CurrPharmDesign.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 501.01 KB

Citation

Please use this url to cite or link to this publication:

MLA
Bultinck, Jennyfer, Sam Lievens, and Jan Tavernier. “Protein-protein Interactions: Network Analysis and Applications in Drug Discovery.” CURRENT PHARMACEUTICAL DESIGN 18.30 (2012): 4619–4629. Print.
APA
Bultinck, J., Lievens, S., & Tavernier, J. (2012). Protein-protein interactions: network analysis and applications in drug discovery. CURRENT PHARMACEUTICAL DESIGN, 18(30), 4619–4629.
Chicago author-date
Bultinck, Jennyfer, Sam Lievens, and Jan Tavernier. 2012. “Protein-protein Interactions: Network Analysis and Applications in Drug Discovery.” Current Pharmaceutical Design 18 (30): 4619–4629.
Chicago author-date (all authors)
Bultinck, Jennyfer, Sam Lievens, and Jan Tavernier. 2012. “Protein-protein Interactions: Network Analysis and Applications in Drug Discovery.” Current Pharmaceutical Design 18 (30): 4619–4629.
Vancouver
1.
Bultinck J, Lievens S, Tavernier J. Protein-protein interactions: network analysis and applications in drug discovery. CURRENT PHARMACEUTICAL DESIGN. 2012;18(30):4619–29.
IEEE
[1]
J. Bultinck, S. Lievens, and J. Tavernier, “Protein-protein interactions: network analysis and applications in drug discovery,” CURRENT PHARMACEUTICAL DESIGN, vol. 18, no. 30, pp. 4619–4629, 2012.
@article{3048154,
  abstract     = {Physical interactions among proteins constitute the backbone of cellular function, making them an attractive source of therapeutic targets. Although the challenges associated with targeting protein-protein interactions (PPIs) -in particular with small molecules are considerable, a growing number of functional PPI modulators is being reported and clinically evaluated. An essential starting point for PPI inhibitor screening or design projects is the generation of a detailed map of the human interactome and the interactions between human and pathogen proteins. Different routes to produce these biological networks are being combined, including literature curation and computational methods. Experimental approaches to map PPIs mainly rely on the yeast two-hybrid (Y2H) technology, which have recently shown to produce reliable protein networks. However, other genetic and biochemical methods will be essential to increase both coverage and resolution of current protein networks in order to increase their utility towards the identification of novel disease-related proteins and PPIs, and their potential use as therapeutic targets.},
  author       = {Bultinck, Jennyfer and Lievens, Sam and Tavernier, Jan},
  issn         = {1381-6128},
  journal      = {CURRENT PHARMACEUTICAL DESIGN},
  keywords     = {small molecule,drug discovery,oncology,virology,SMALL-MOLECULE INHIBITOR,CHEMICAL CROSS-LINKING,INTERACTION DATABASE,INTERACTION DATASETS,MASS-SPECTROMETRY,SYSTEMS BIOLOGY,DISEASE GENES,THERAPEUTIC SUPPRESSION,HUNTINGTONS-DISEASE,SUBNETWORK MARKERS,interactome,Protein-protein interaction},
  language     = {eng},
  number       = {30},
  pages        = {4619--4629},
  title        = {Protein-protein interactions: network analysis and applications in drug discovery},
  volume       = {18},
  year         = {2012},
}

Web of Science
Times cited: